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A B S T R A C T The immunological responsiveness of a panel of 17 patients with systemic lupus erythematosus (SLE) was studied in an in vitro model of xenogeneic sensitization against mouse lymphoid cells. Generation ofcytotoxic thymus-derived (T) cells evaluated by a chromium release assay against labeled target cells was found to be drastically impaired in these lupus patients. Such depression was independent of drug therapy at the time of the study, clinical status, and other immunological parameters such as antibodies against native DNA, complement levels, cryoglobulinemia, circulating immune complexes, or T-and bone marrow-derived (B)-cell numbers. In contrast to the cytotoxic response, the proliferative responses to phytohemagglutinin, to allogeneic lymphocytes, and to xenogeneic lymphocytes were not significantly different from those of normal individuals. The latter response was shown to be H-2 restricted with the primed lymphocyte test. These results suggest the presence of a selective defect in the generation or in the expression of killer cells rather than a deficiency in antigen recognition by T cells. The role of serum factor(s) was examined by educating the lymphocytes of normal subjects in the presence of serum from SLE patients. Such manipulation affected both the generation of killer cells and the proliferative response. Finally our observations indicate that depression of cell-mediated immunity in SLE patients may be associated with several mechanisms including a cellular one, specifically affecting the generation of killer T cells, and a humoral one possibly as a result of antilymphocytic antibodies and(or) immune complexes.
INTRODUCTION
The immunological etiology of systemic lupus erythematosus (SLE)l is now well-accepted (1) (2) (3) , yet the precise nature of the immunological imbalance that leads to the disease onset is still hypothetical (4) . Various types of autoantibodies binding to cellular components can be detected (5) . It is likely that such antibodies play a significant role in the onset of some of the organ manifestations of the disease, such as nephritis or arthritis (6, 7) . However, it is still not clear whether they represent the primary event in the pathogenesis of the disease, or rather a consequence of a more primitive defect that triggers off aberrant clones of autoantibody-producing cells (8, 9) . The latter hypothesis has prompted numerous investigators to evaluate the thymus-derived (T)-cell-mediated responsiveness of SLE patients.
We have recently shown that human peripheral blood lymphocytes (PBL) can be educated against mouse cells to differentiate into H-2-specific cytotoxic T cells (10) . This model offers the possibility to evaluate a well-defined T-cell function, namely the generation of killer cells, under conditions where the HLA haplotype of the responder should supposedly not interfere with the magnitude of the response. We have applied this model to the study of cellular immunological reactivity of 17 
METHODS
Patients and control subjects (Table I) 17 patients with SLE, defined by the American Rheumatism Association criteria (11) were compared with 20 control subjects: 13 normal individuals from the local bloodbank and 7 hospitalized patients (5 with chronic renal failure without hemodialysis and without treatment, and 2 untreated urological patients). All SLE patients were female: 4 presented a major exacerbation at the time of the test, 10 had a mild or moderate activity, and 3 could be considered as inactive. The degree of disease activity graded from one to four integrates both the number of organs involved and the severity of the lesions, and was independently evaluated by two physicians. All patients had shown major humoral abnormalities characteristic of SLE (anti-native DNA antibodies, low C3) in the past. Treatment at the time of the test consisted of prednisone ancl cyclophosphamide (three cases) or prednisone alone (five cases). Two patients received indomethacin and another one hydroxychloroquine sulfate. Six patients were not receiving medications at the time of the study. Among these six patients four (Patients 3, 7, 8, 11) had never received any treatment, whereas the other two had been off therapy for more than 6 mo when the investigation was performed.
Mononuclear cell isolation
Peripheral blood was drawn aseptically into a 50-ml syringe (Terumo, Tokyo, Japan) containing preservative-free heparin (Liquemine, Roche, Paris, France), 10 IU/ml of blood. The blood was diluted at 1:3 with Hanks' balanced salt solution (HBSS) (Institut Pasteur, Paris, France). 30-ml aliquots were layered on 10 ml of a Ficoll-Angiocontrix mixture (1,077 specific density): 24 parts of 9% wt/vol Ficoll (Pharmacia, Uppsala, Sweden) and 10 parts of a 30% solution of iothalamate sodium (Angiocontrix, Guerbet, Paris, France) in 50-ml plastic conical tubes (2070, Falcon Labware, Div. Becton, Dickinson & Co., Oxnard, California). The tubes were centrifuged at room temperature at 400 g for 20 min and the opalescent lymphocyte-enriched ring was pipetted off. Mononuclear cells were spun down at 600 g for 10 min, and the cell pellet washed three times in HBSS at 400 g for 5 
Xenogeneic MLC test
Human PBL were diluted in culture medium (see above) at the concentration of 1 x 106 cells/ml; mitomycin C-treated mouse spleen cells were adjusted in the same medium to a final concentration of 1 x 107 cells/ml; 0.1-ml aliquots from each cell suspension were mixed in the wells of flat-bottomed tissue culture microplates (3040, Falcon Labware). The cell mixtures were cultured at 37°C in a 5% CO2 humid atmosphere and pulsed at day 3 
CML assay
Ascites fluid-containing tumor cells was drawn from the peritoneal cavity and immediately diluted into saline plus heparin (10 IU/ml). The tumor cell suspension was washed twice, and counted in Turk's solution. 5 million cells were labeled for 1 h at 37°C with 100 IuCi of 51Cr (sodium chromate, Commissariat a l'Energie Atomique, sp act, 143 mCi/mg) in a final vol of 0.25 ml. Target cells were subsequently washed three times in HBSS and resuspended in culture medium; 1 x 104 chromium-labeled target cells were dispensed into each well of round-bottom microculture plates (Cooke Engineering, Alexandria, Va.) and various amounts of educated or noneducated PBL (from 100 effectors to 1 target down to 12.5/1) were added. Noneducated PBL were cultured alone for 7 d in the absence of mouse cells. The plates were incubated at 37°C in a 5% CO2 humid atmosphere for 16 h. At the end of incubation, they were centrifuged at 600 g for 5 min at 4°C, and 100 ,ul of supemate was removed from each well and counted in a Packard Autogamma scintillation spectrometer. Maximum chromium release was measured after addition of detergent (RBS, Microbiological Associates). Spontaneous release, i.e., release from target cells incubated alone never exceeded 35% of the maximum chromium release. Percentage of specific release was calculated as follows: sensitized lymphocytes (counts per minute) - Erythrocyte (E) rosette formation (12) . E rosettes were formed by mixing 3 x 107 fresh sheep erythrocytes (SRBC) (Institut Pasteur, Paris, France) with 1 x 106 human PBL in HBSS supplemented with 20% human AB serum, previously absorbed volume to volume with packed SRBC. Cell mixtures were incubated for 30 min at 37°C, centrifuged for 5 min at 200 g, and stored overnight at 40C before being gently resuspended on a roller (Apelab, Paris, France) and counted in a hematocytometer. Leukocytes surrounded by three or more SRBC were counted as rosettes.
Erythrocyte-antibody-complement rosette formation (13) .
SRBC were washed three times in HBSS, resuspended to 2% in HBSS and incubated volume to volume with diluted rabbit anti-SRBC serum (Institut Pasteur) at 37°C for 30 min. The antiserum dilution was determined according to its subagglutinating titer. The antibody coated SRBC were washed three times in veronal buffer at 800 g and mixed volume to volume with fresh mouse serum of CFI strain diluted 1:20 in HBSS. After 30-min incubation at 37°C and three washes in veronal buffer, the sensitized SRBC (3 x 107) were mixed with 1 x 106 human PBL in HBSS. Tubes were incubated for 30 min at 37°C and rosette counting was done in a hematocytometer, after gentle resuspension on a roller.
Anti-DNA antibody determination. Antibodies to DNA were detected by a Farr test (14) using 14C-labeled DNA from Escherichia coli. (Amersham Corp., Arlington Heights, Ill.). Bindings above 20% were considered as abnormal.
Determination of C3 and C4 serum levels. Complement fractions C3 and C4 were measured using radial immunodiffusion plates (C3 immunoplates purchased from Hyland Laboratories, Los Angeles, Calif., and C4 immunoplates purchased from Behring Institute, Paris, France).
Cryoglobulin determination. The blood was drawn at 370C and kept at this temperature until the serum was separated. The cryoglobulins were defined by the presence of a precipitate after 8-d storage at +40C.
Determination ofcirculating immune complexes (15) . Circulating immune complexes were determined by the technique of precipitation by polyethylene-glycol (PEG 6,000, Fluka, Buchs, Switzerland). 4 ml of a 7% polyethylene-glycol solution in borate buffer (0.1 M, pH 8.4) were mixed with 4 ml of serum diluted 1:25 in the same buffer. After 18 h incubation at 40C, the tubes were centrifuged at 20,000 g for 20 min. The supernates were discarded and the precipitates dissolved in 5 ml of NaOH 0.1 N. The quantity of precipitated proteins was read by optical density at 280 nm with a spectrophotometer (Beckman Instruments, Inc., Paris, France). When abnormal precipitate was observed the amount of globulin and C4 present in the precipitate was evaluated as described (15 Fig. 1 . Educated lymphocytes from the SLE patients showed an almost complete absence ofcytotoxic reactivity. Such lack of responsiveness occurred with all SLE patients' lymphocytes, irrespective of their clinical, therapeutical, and immunological status (for details see Table I ). We also tested PBL from 13 normal individuals belonging to the local blood bank and PBL from 7 non-SLE patients (5 with chronic renal failure without being hemodialyzed, and 2 with urological disorders but normal renal function). Among the 13 normal donors, 10 gave a significant cytotoxic response (Fig. 1) . On three occasions, these PBL, educated against DBA/2 spleen cells (H-2d), were also assayed against EL4 targets (H-2b The antigen specificity of the blastogenic response was also checked for both SLE and normal PBL confirming the H-2 restriction already described in cell-according to the method described by Lindhal and mediated xenogeneic reactions (16) (17) (18) . Educated PBL Bach (18) . Namely anti-DBA/2-educated PBL were left from three normal subjects showed only slight cytotox-for 9 d in culture, and then restimulated with H-2-comicity against the relevant (H-2d) target cells in spite of a patible or -incompatible irradiated spleen cells. As Table IV , 5% and 10% SLE serum caused a dramatic inhibition of proliferation of both normal and SLE lymphocytes. 1% serum was apparently insufficient to significantly modify the reaction. It should be noted that similar inhibition was also observed when SLE serum was tested on autologous SLE lymphocytes indicating that the effect could not be attributed to natural alloantibodies. The next step consisted in evaluating the effect of SLE serum on the generation of cytotoxic T cells from PBL of normal donors. The presence of 10% SLE serum during education resulted in a total abrogation ofthe cytotoxic response (Table V) . On the other hand, preincubating the PBL with SLE serum before education in normal medium did not alter the response (Table V, experiment 3). A total offive different SLE sera were tested in mixed lymphocyte cultures. All of them induced a severe inhibition of the reaction. Three of them tested in macroculture-generating xenogeneic cytotoxic cells also prevented the appearance of effector cells. Because the sera were obtained from patients either on or off therapy, and because some did contain, whereas others did not contain, abnormal levels of immune complexes and cryoglobulins, it is apparent that these factors are not directly involved in the inhibitory properties of SLE sera.
DISCUSSION
This study demonstrates the occurrence of a striking impairment among SLE patients of their capacity to generate cytotoxic cells in vitro. Indeed, all patients examined disclosed an almost total unresponsiveness against xenogeneic target cells compared to the 80% good responders found among normal donors and non-SLE patients. This immunological abnormality seems, however, relatively restricted to this particular function because we found other immunological parameters such as T-cell number or T-cell stimulation by lectins to be within the normal range, an observation which is in agreement with several other reports. Some authors have reported minor T-cell abnormalities in SLE patients yet these were essentially described during exacerbation phases (25) (26) (27) and in this study only three patients were in such an active stage.
As a matter of fact, the literature dealing with the cell-mediated reactivity of SLE patients is controversial. Skin tests, for instance, have been found to be either normal (28, 29) or lower than control values (30) (31) (32) (33) (34) . The blastogenic response to phytohemagglutinin or to alloantigens has been found normal in some instances (28, 29, 31, 35, 36) and depressed in others (37) (38) (39) . Values for percentage of peripheral T cells have been found highly variable from patient to patient (40) (41) (42) (43) .
It has been shown previously that the cytotoxic cells that are generated in a xenogeneic mixed lymphocyte reaction are of T origin, and recognize specifically H-2 K or H-2 D gene products (10, (16) (17) (18) . Furthermore, we have recently observed (a) that the cytotoxic reaction was not inhibited by the presence in the medium of heat-aggregated immunoglobulins, nor by immune complexes and (b) that supernates from xenogeneic mixed leukocyte cultures were unable to induce cytotoxicity either per se or after the addition of naive PBL Xenogeneic Cell-Mediated Lympholysis in Lupus Patients (47) and SLE patients (48) . An alternative hypothesis implies that the lack of functional cytotoxic T cells detected in SLE patients is a direct consequence of the presence of autoantibodies directed against lymphocytic antigens. Such autoantibodies have been detected by several groups in the serum of SLE patients (24, (51) (52) (53) (54) (55) as well as in the serum of NZB mice (49, 50) . In a large survey of our patients (not including those ofthe present panel) it was found that 28 out of 39 had anti-lymphocytic autoantibodies.2 The fine specificity of these antibodies is however still unclear. Some show relative restriction against T cells (24) , whereas others are directed against both T and B lymphocytes (51) ; some seem to be restricted to "self" HLA (52, 53), others not (54, 55) . In the light of the present results these autoantibodies would be One might hypothesize that the same serum inhibitors whose activity is demonstrated in vitro, already impair in vivo the potential reactivity of PBL from SLE patients. However, this hypothesis is not favored by the finding that SLE serum can further inhibit the proliferative response of autologous SLE lymphocytes wheni added in vitro to the ctulture mediumiii althlough these lymphocytes were already in contact with the same serum in vivo, and the observation that the preincubation of normal donor PBL with SLE serum for 2 h at 37°C does not lead to the inactivation of these lymphocytes when they are later educated in normal AB serum. Thus the in vitro inhibition of lymphocyte responses by SLE serum factors, is probably not a simple mimicry of what occurs in vivo on the PBL of SLE patients. This conclusion does not preclude however the possibility that the in vivo immune deficit might have a humoral origin.
Some of the SLE sera tested for in vitro inhibition of MLC and CML contained high amounts of immune complexes. Others did not, but this may just have reflected a relative lack of sensitivity of the detecting assay. Some T-cell subsets and, in particular, activated T lymphocytes (57) express Fc receptors and might therefore fix complexes. It remains to be determined however to what extent the occupation of Fc receptors by immune complexes may modify the functions of educated T cells. One should note, in that regard, that the shedding of Fc receptors at 37°C has no repercussioIn upon the cytolytic capacity of educated T lymphocytes (58) .
In conclusion, two salient features emerge from this study on the immune responsiveness of SLE patients. One is the incapacity of such patients' T lymphocytes Xenogetneic Cell-Mledliated Lyjmpholysis in Lupus Patients "In those cultures the medium contained a mixture of 10% SLE serum and 10% AB serum. ¶ PBL were first incubated at 37°C for 2 h in 10% SLE serum, then washed twice and finally resuspended in medium enriched with 20% AB serum.
to express significant cytotoxicity against xenogeneic target cells, in spite of a normal proliferative response in MLC. The other is the inhibitory effect of their serum on T-cell proliferation and generation of cytolytic cells.
It is at present difficult to decide whether these two observations are independent manifestations of the same disease or whether they are related in a way that remains to be determined? No simple experiment can provide a definitive answer to such a basic question posed for all studies of cellular parameters in human lupus. This important reservation does not detract interest from the whole problem of evaluating T cell-mediated immunity in human or murine lupus but urges for caution in interpreting the results in terms of the pathogenesis of the disease.
